Tests CCS1477 (inobrodib) alone or with other drugs in blood cancers
Tests CCS1477 (inobrodib) in adults with advanced blood cancers, including leukemia and lymphoma.
Key facts
- Who runs it
- CellCentric Ltd.
- Where
- Bebington, Bristol, Cardiff, Derby, Edinburgh, Glasgow, Leicester, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford, Southampton, Stoke-on-Trent, and Sutton, United KingdomSee the 18 sitesAlso in 4 other countries, 21 sites
- Trial code
- Registry title
- Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 250 people, planned
- Started
- 9 Aug 2019
- Expected to end
- 31 Mar 2027
- Type of study
- Interventional, 6 groups
- Treatments tested
- CCS1477
- Pomalidomide
- Dexamethasone
- Azacitidine
- Venetoclax
- Bortezomib
- Ixazomib
- Elranatamab
- Teclistamab
- Lenalidomide
- Daratumumab
- Record updated
- 24 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose blood cancer (NHL, multiple myeloma or AML) has come back or has not responded to treatment, and who have already had standard therapy.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Confirmed relapsed or refractory haematological malignancies (NHL, MM and AML). ECOG performance status 0-2.
- Earlier treatment
- Must have previously received standard therapy.
Main reasons for not taking part
- Chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose
- Major surgery or significant injury within 4 weeks of the first dose
- Severe or uncontrolled systemic disease or other uncontrolled illness
- QTcF prolongation (> 470 msec)
- Certain medicines (strong CYP3A4 inhibitors or inducers, CYP2C8 substrates with a narrow therapeutic range) taken within the stated time before the first dose
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Provision of consent
- ECOG performance status 0-2
- Patients with confirmed (per standard disease specific diagnostic criteria), relapsed or refractory haematological malignancies (NHL, MM and AML)
- Must have previously received standard therapy
- Adequate organ function
Who cannot take part
- Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose
- Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment
- Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
- Patients should discontinue statins prior to starting study treatment
- Any unresolved reversible toxicities from prior therapy >CTCAE grade 1 at the time of starting study treatment (except alopecia and grade 2 neuropathy)
- Any evidence of severe or uncontrolled systemic diseases
- Any known uncontrolled inter-current illness
- Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment
- CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
- QTcF prolongation (> 470 msec)
Where in United Kingdom
Also in 4 other countries, 21 sites
- The Clatterbridge Cancer Centre NHS Foundation TrustBebington, United KingdomContact: Gillian Brearton, MDTaking people
- University Hospitals BristolBristol, United KingdomContact: Sally Moore, MDTaking people
- University Hospital of WalesCardiff, United KingdomContact: Steven KnapperTaking people
- Royal Derby HospitalDerby, United KingdomContact: Firas Al-Kaisi, MDTaking people
- Western General HospitalEdinburgh, United KingdomContact: Victoria CampbellTaking people
- Gartnavel General HospitalGlasgow, United KingdomContact: Jennifer TraversTaking people
- Leicester Royal InfirmaryLeicester, United KingdomContact: Harriet WalterTaking people
- Imperial CollegeLondon, United KingdomContact: Aristeidis ChaidosTaking people
- NIHR University College London Clinical Research FacilityLondon, United KingdomContact: Jenny O'NionsTaking people
- Sarah Cannon Research Institute UKLondon, United KingdomContact: Richard DillonTaking people
- St. Bartholomew's HospitalLondon, United KingdomContact: Heather OakerveeTaking people
- The Christie HospitalManchester, United KingdomContact: Tim SomervailleTaking people
- Newcastle upon Tyne HospitalsNewcastle upon Tyne, United KingdomContact: Thomas CreaseyTaking people
- Nottingham University Hospitals NHS TrustNottingham, United KingdomContact: Dean SmithTaking people
- Cancer and Haematology CentreOxford, United KingdomContact: Sarah GoodingTaking people
- University Hospital of SouthamptonSouthampton, United KingdomContact: Andy DaviesTaking people
- Royal Stoke University HospitalStoke-on-Trent, United KingdomContact: Kamaraj KarunanithiTaking people
- The Royal MarsdenSutton, United KingdomContact: Charlotte PawlynTaking people
About the trial
What the trial wants to find out
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
The 6 groups in the trial
- CCS1477 dose escalation NHL/MMTreatment being tested
CCS1477 monotherapy
Treatment: CCS1477
- CCS1477 dose escalation AML/Higher risk MDSTreatment being tested
CCS1477 monotherapy
Treatment: CCS1477
- CCS1477 monotherapy expansion and combination dose finding and expansion NHLTreatment being tested
CCS1477 monotherapy, CCS1477 combination with lenalidomide
Treatment: CCS1477 and Lenalidomide
- CCS1477 monotherapy expansion and combination dose finding and expansion - MMTreatment being tested
CCS1477 monotherapy, CCS1477 combination with pomalidomide-dexamethasone, CCS1477 combination with bortezomib-dexamethasone, CCS1477 combination with ixazomib-dexamethasone, CCS1477 combination with elranatamab, CCS1477 combination with teclistamab, CCS1477 combination with lenalidomide, CCS1477 combination with lenalidomide and daratumumab
Treatment: CCS1477, Pomalidomide, Dexamethasone, Bortezomib, Ixazomib, Elranatamab, Teclistamab, Lenalidomide, and Daratumumab
- CCS1477 monotherapy expansion and combination dose finding and expansion - AMLTreatment being tested
CCS1477 monotherapy, CCS1477 combination with azacitidine, CCS1477 combination with azacitidine and venetoclax
Treatment: CCS1477, Azacitidine, and Venetoclax
- CCS1477 monotherapy expansion and combination dose finding and expansion - Higher risk MDSTreatment being tested
CCS1477 monotherapy, CCS1477 combination with azacitidine
Treatment: CCS1477 and Azacitidine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.
- Plain-language title
- Tests CCS1477 (inobrodib) alone or with other drugs in blood cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 24 June 2026